Skip to main content

Table 4 Spearman’s rank correlation coefficients between change from baseline to week 12 in CMV or EBV viral load, or CRP level, and change in lymphocyte sub-populations

From: Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis

Change in outcome variables, rho (p value)

Lymphocyte sub-populations

T (CD3+)

TH(CD3+/CD4+)

TC(CD3+/CD8+)

B (CD19+)

NK (CD16+/CD56+)

CMV viral load, copies/500 ng total DNA

−0.0499 (0.5742)

−0.0889 (0.3164)

0.0020 (0.9817)

−0.0530 (0.5505)

−0.0148 (0.8674)

EBV viral load, copies/500 ng total DNA

0.1872 (0.0351)

0.1970 (0.0264)

0.1711 (0.0544)

0.2491 (0.0047)

0.0033 (0.9709)

CRP level, mg/L

−0.2832 (0.0008)

−0.2644 (0.0017)

−0.2009 (0.0181)

−0.3996 (0.0000)

0.0699 (0.4152)

  1. The correlation analyses presented above were performed using pooled data from the placebo and tofacitinib groups.
  2. B, B cells; CMV, cytomegalovirus; CRP, C-reactive protein; DNA, deoxyribonucleic acid; EBV, Epstein-Barr virus; NK, natural killer cells; rho, Spearman’s rank correlation coefficient; T, total T cells; TH, T helper cells; TC, cytotoxic T cells.
Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us